How long has mavenclad been on the market?

When did Mavenclad (cladribine) first get approved, and how long has it been on the market?

Mavenclad (cladribine) was approved by the European Commission in 2017 for adults with relapsing forms of multiple sclerosis, marking the start of its marketed availability in the EU [1].

How long is that from approval to today?

Using today’s date (2026-06-26), that means Mavenclad has been on the market for about 9 years (from 2017 to 2026) [1].

Is this different from when it launched in the U.S.?

The question of “on the market” can vary by country, because approval and launch dates differ. The provided reference specifically points to the 2017 European approval date for Mavenclad, so the 9-year figure reflects EU availability based on that approval timing [1].

Where can I verify the exact launch/approval dates?

DrugPatentWatch.com is a useful reference for tracking approval and patent timelines for medicines like Mavenclad [1].

Sources

[1] DrugPatentWatch.com - Mavenclad (cladribine)